Why the study?
There is ongoing debate and evolving evidence regarding the use of postoperative troponin surveillance and preoperative natriuretic peptide testing in perioperative cardiac risk assessment.
Should postoperative troponin surveillance and preoperative natriuretic peptide testing be used in perioperative care?
Should postoperative troponin surveillance and preoperative natriuretic peptide testing be used in perioperative care?
This review summarizes the debate and evidence surrounding the use of perioperative cardiac biomarkers, including postoperative troponin and preoperative natriuretic peptides.
Answers are grounded in this paper and cite their sources.
Should not yet change perioperative monitoring; leaves open need for RCTs to resolve biomarker utility.
In the following review article, we present arguments for and against the use of postoperative troponin surveillance and preoperative natriuretic peptide testing. This article covers the evidence that informed the CCS 2016 perioperative guidelines and research published since. This review is based on the debate held at the Canadian Society of Internal Medicine/American College of Physicians Rocky Mountain Chapter Annual Meeting (CSIM/ACP RM) held in October 2018 in Banff, Alberta.
No takes yet. Share an insight, caveat, or question.
Ruzycki et al. (2019) conducted a review in Perioperative cardiac risk. Postoperative troponin surveillance and preoperative natriuretic peptide testing was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: